Form 4: SCPH Director's Options Converted in MannKind Merger

scPharmaceuticals Director Sara Bonstein's stock options were cancelled and converted into cash and Contingent Value Rights following the completion of a tender offer by MannKind Corporation.

Summary

• scPharmaceuticals Inc. Director Sara Bonstein's stock options were cancelled and converted into cash and Contingent Value Rights (CVRs) on October 7, 2025.
• This action followed the completion of a tender offer by Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of MannKind Corporation, as part of a merger agreement dated August 24, 2025.
• Options to purchase common stock that were outstanding and unexercised with an exercise price per share less than $5.35 were cancelled.
• Holders received a cash payment equal to the total number of shares subject to the option multiplied by the difference between $5.35 and the option's exercise price.
• Additionally, one CVR was issued for each share subject to the cancelled option.
• Bonstein's cancelled options included 30,000 at an exercise price of $3.85, 19,750 at $4.11, and 16,300 at $4.53.
• This resulted in a total cash payment of $82,856 and 66,050 CVRs for Bonstein.

Sentiment

Score: 7

Explanation: The transaction provides immediate liquidity for in-the-money options and potential future value via CVRs, which is generally a positive outcome for option holders in an acquisition. It represents a definitive outcome for the company's acquisition.

Positives

• The completion of the merger provides liquidity for in-the-money option holders, converting their options into a defined cash value.
• The issuance of Contingent Value Rights (CVRs) offers potential future value to option holders based on specific contingent events post-merger.

Negatives

• The cancellation of stock options means option holders no longer participate directly in any future appreciation of scPharmaceuticals' stock.
• The value of the Contingent Value Rights (CVRs) is contingent and uncertain, depending on future performance or milestones.

Risks

• The value of the Contingent Value Rights (CVRs) is inherently uncertain and depends on the achievement of specific future events or performance metrics, which may not materialize.
• Option holders no longer have direct equity exposure to scPharmaceuticals Inc. following the merger, limiting their participation in any potential upside beyond the CVRs.

Future Outlook

The independent future outlook for scPharmaceuticals Inc. is limited due to the completion of its acquisition by MannKind Corporation. The future value for former option holders now depends on the performance and terms associated with the Contingent Value Rights (CVRs) received.

Industry Context

The acquisition of scPharmaceuticals Inc. by MannKind Corporation reflects ongoing consolidation within the pharmaceutical and biotechnology sectors, where larger entities often acquire smaller companies for their pipeline assets or market access. The treatment of stock options and the use of CVRs are common mechanisms in such transactions to provide liquidity to option holders and align future incentives.

Stakeholder Impact

• **Shareholders:** Received cash for their tendered shares as part of the merger, concluding their investment in scPharmaceuticals Inc.
• **Option Holders (like Sara Bonstein):** Received cash for in-the-money options and CVRs, providing liquidity and potential future value, but ending direct equity participation in the acquired entity.
• **Employees:** While not explicitly detailed in this filing, mergers often lead to organizational restructuring and potential impacts on employment for the acquired company's workforce.

Next Steps

• The value and realization of the Contingent Value Rights (CVRs) will depend on future events and performance as defined in the merger agreement.

Key Dates

Keywords

scPharmaceuticals, SCPH, MannKind, Merger, Tender Offer, Stock Options, Form 4, Insider Transaction, Contingent Value Right, CVR, Sara Bonstein